Diagnostics: Page 5
-
Courtesy of Roche
Roche sues Foresight and Stanford, alleging use of trade secrets
Roche said Stanford applied for patents relating to cancer detection and monitoring technology using its confidential information.
By Nick Paul Taylor • July 3, 2024 -
Courtesy of U.S. Food and Drug Administration
Cepheid wins FDA nod for fingerstick hepatitis C test
Patients could be diagnosed and potentially receive treatment at the same healthcare visit.
By Nick Paul Taylor • June 28, 2024 -
David Ryder via Getty Images
FDA partners with Gates Foundation to support breath-based diagnostic development
Through a $1.9 million Gates Foundation grant, the collaborators will create methods to help developers make tests that can easily be deployed to rural and remote areas.
By Nick Paul Taylor • June 27, 2024 -
Courtesy of Grail
Illumina completes Grail spinoff
Nearly four years after Illumina announced a deal to buy Grail, the liquid biopsy maker will debut on Nasdaq Tuesday as a standalone company.
By Nick Paul Taylor • June 25, 2024 -
Retrieved from Dermtech on June 20, 2024
Dermtech files for Chapter 11, lays off 20% of staff
The diagnostic test maker will continue to hunt for a buyer for its skin cancer detection patch.
By Nick Paul Taylor • June 20, 2024 -
Permission granted by Agilent
Agilent to cut 3% of employees as sluggish lab equipment market persists
An Agilent spokesperson said the layoffs follow job cuts announced late last year amid a slower-than-expected market recovery.
By Susan Kelly • June 14, 2024 -
Permission granted by Danaher
Danaher names Martin Stumpe as chief data and AI officer
Martin Stumpe will take over the new position after previously working as Tempus’ chief of AI and the head of Google’s pathology team.
By Nick Paul Taylor • June 6, 2024 -
Dr_Microbe via Getty Images
Saliva test identifies men at high risk of prostate cancer
Data presented at the American Society of Clinical Oncology meeting suggest the test can support prostate cancer diagnosis in people who are missed by other screening methods.
By Nick Paul Taylor • June 5, 2024 -
Courtesy of Grail
Illumina board approves Grail spinoff
Leerink Partners analyst Puneet Souda said Grail, with a cash burn of $532 million in 2023, is likely to remain “a cautionary tale in diagnostics for years to come.”
By Susan Kelly • June 4, 2024 -
Courtesy of Illumina
Illumina names Everett Cunningham as chief commercial officer
Cunningham will join Illumina from Exact Sciences to end the six-month search for a permanent leader.
By Nick Paul Taylor • June 4, 2024 -
K-Kwanchai via Getty Images
Lab industry sues to stop FDA’s new LDT rule
The American Clinical Laboratory Association argues the agency does not have the authority to enforce stricter standards on lab developed tests.
By Susan Kelly • May 30, 2024 -
Courtesy of GuardantHealth
FDA panel backs Guardant’s blood test for colon cancer
“The favorable panel vote does not by any means imply this test will become an overnight success,” wrote William Blair analyst Andrew Brackmann.
By Susan Kelly • May 24, 2024 -
Courtesy of Cue Health Press Kit
Cue Health to lay off remaining employees, shut down
Once a COVID-testing darling, Cue will close after raising hundreds of millions of dollars and striking high-profile partnerships with Google and the NBA during the pandemic.
By Elise Reuter • May 22, 2024 -
Courtesy of Business Wire
Guardant colon cancer test struggles to detect non-cancerous tumors, FDA says
Agency scientists highlighted the risk in materials posted ahead of a Thursday advisory panel meeting for the Guardant Health blood test.
By Susan Kelly • May 22, 2024 -
Carl Court via Getty Images
EMA updates advice on drug-device combinations under MDR, IVDR
The European Medicines Agency answered six new questions to clarify topics such as how companies can get advice on borderline products.
By Nick Paul Taylor • May 22, 2024 -
Permission granted by Becton Dickinson
BD wins FDA approval for cervical cancer screening self-collection kit
Patients can self-collect the samples in locations such as retail pharmacies, which could encourage more people to get tested.
By Nick Paul Taylor • May 17, 2024 -
Courtesy of Cue Health Press Kit
FDA advises against using Cue Health COVID-19 tests, sends warning letter
Agency inspectors found Cue made unauthorized changes to its COVID-19 kits that “reduced the reliability of the tests.”
By Nick Paul Taylor • May 14, 2024 -
Courtesy of Pacific Biosciences
Pacific Biosciences to lay off 195 employees as part of cost cuts
More than half of the job losses stem from the closure of the genome sequencer’s San Diego office amid an ongoing industry slump.
By Susan Kelly • May 14, 2024 -
Courtesy of Samsung
Samsung Medison to buy AI ultrasound company Sonio
Sonio’s software uses deep learning to improve image quality. Its software will remain compatible with all ultrasound machines, the company said.
By Elise Reuter • May 8, 2024 -
Sarah Silbiger via Getty Images
Geneoscopy wins FDA approval for Labcorp-partnered colon cancer test
Evercore and Cowen analysts expect Colosense to have a limited impact on Exact Sciences’ rival Cologuard test.
By Nick Paul Taylor • May 8, 2024 -
Nuthawut Somsuk via Getty Images
Karius raises $100M to expand access to multi-pathogen blood test
Karius plans to use the funding to expand the test outside of the hospital setting and support research of the company’s DNA technology beyond infectious diseases.
By Nick Paul Taylor • May 6, 2024 -
Courtesy of QuidelOrtho
QuidelOrtho names ex-Abbott exec Brian Blaser as CEO
Blaser is coming out of retirement to take charge of QuidelOrtho, after the diagnostics company fired former CEO Doug Bryant in February.
By Nick Paul Taylor • May 3, 2024 -
sanjeri via Getty Images
Lab test overhaul: FDA to regulate LDTs as medical devices
Stricter review of new tests developed by laboratories is coming, but some fear the changes will be expensive, time-consuming and discourage innovation.
By Susan Kelly • May 3, 2024 -
Courtesy of Quest Diagnostics
Quest to ramp up AI capabilities with purchase of PathAI’s diagnostic lab
PathAI is selling its diagnostics assets, including a Tennessee laboratory, but will continue to support its biopharmaceutical customers.
By Nick Paul Taylor • May 2, 2024 -
Jon Cherry via Getty Images
FDA defends LDT final rule, while critics fear it upends lab industry
The new policy aims to ensure important diagnostics remain available to patients, but some experts caution the increased regulatory burdens could slow access to testing.
By Susan Kelly • April 30, 2024
Previous
